Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.9%

4 terminated/withdrawn out of 31 trials

Success Rate

78.9%

-7.6% vs industry average

Late-Stage Pipeline

10%

3 trials in Phase 3/4

Results Transparency

33%

5 of 15 completed trials have results

Key Signals

3 recruiting5 with results

Enrollment Performance

Analytics

Phase 2

18(78.3%)

Phase 3

3(13.0%)

Phase 1

1(4.3%)

N/A

1(4.3%)

23Total

Phase 2(18)

Phase 3(3)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (31)

Showing 20 of 31 trials

NCT01820910Phase 2Completed

Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment

Role: lead

NCT03697512Phase 2Active Not Recruiting

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Role: lead

NCT05735834Phase 3Active Not Recruiting

Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Role: lead

NCT01011920Phase 2Completed

Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Role: lead

NCT07376330Not Yet Recruiting

Molecular and Cellular Characterization of MALT Lymphoma

Role: lead

NCT04333524Active Not Recruiting

FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role

Role: lead

NCT05700149Recruiting

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Role: lead

NCT06712459Recruiting

Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

Role: lead

NCT01808599Phase 2Active Not Recruiting

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

Role: lead

NCT01599559Not ApplicableActive Not Recruiting

Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma

Role: lead

NCT07147751Not Yet Recruiting

Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach

Role: lead

NCT02329080Phase 2Completed

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

Role: lead

NCT00945724Phase 2Completed

Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis

Role: lead

NCT03495960Phase 2Completed

Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

Role: lead

NCT04646395Phase 2Active Not Recruiting

Study of Acalabrutinib and Tafasitamab in MZL Patients

Role: lead

NCT03031483Phase 2Completed

Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma

Role: lead

NCT04417166Phase 2Recruiting

Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma